


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



溫州康寧醫院股份有限公司
Wenzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China)

Stock code: 2120

**PRINCIPAL OPERATING DATA AND INDICATORS
FOR THE THREE MONTHS ENDED MARCH 31, 2022
AND THE FIRST QUARTER 2022**

This announcement is made by Wenzhou Kangning Hospital Co., Ltd. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance to keep the shareholders of the Company and potential investors informed of the latest business developments of the Company and its subsidiaries (the “**Group**”).

References are made to the announcements of the Company dated January 30, 2022, March 15, 2022, March 21, 2022, March 31, 2022 and April 1, 2022 respectively (the “**Announcements**”). Unless the context otherwise requires, the capitalised terms used herein shall have the same meanings as those defined in the Announcements.

The table below sets forth the relevant operating data and indicators of the Group’s owned hospitals by inpatients and outpatients for the three months ended March 31, 2022 with comparative figures for the three months ended March 31, 2021:

	For the three months ended March 31,		
	2022	2021	Year-on-year changes
Inpatients			
Number of inpatient bed-days	718,866	609,867	17.9%
Average inpatient spending per bed-day on treatment and general healthcare services (<i>RMB</i>)	339	321	5.6%
Average inpatient spending per bed-day on pharmaceutical sales (<i>RMB</i>)	50	57	-12.3%
Total average inpatient spending per bed-day (<i>RMB</i>)	389	378	2.9%
Outpatients			
Number of outpatient visits	112,280	72,146	55.6%
Average outpatient spending per visit on treatment and general healthcare services (<i>RMB</i>)	112	138	-18.8%
Average outpatient spending per visit on pharmaceutical sales (<i>RMB</i>)	316	377	-16.2%
Total average outpatient spending per visit (<i>RMB</i>)	428	515	-16.9%

Note: The above data of number of outpatient visits and average outpatient spending per visit on treatment and general healthcare services are excluding the business of the COVID-19 nucleic acid test.

The above operating data and indicators are based on the Company's records and have not been audited or reviewed by the Company's auditors. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

CONTINUED TRADING SUSPENSION

At the request of the Company, trading in the shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on April 1, 2022. Trading in the shares of the Company will remain suspended until further notice.

By order of the Board
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
Chairman

Zhejiang, the PRC

April 4, 2022

As of the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Ms. WANG Hongyue; the non-executive directors are Mr. QIN Hao and Mr. LI Changhao; and the independent non-executive directors are Mr. ZHAO Xudong, Ms. ZHONG Wentang and Mr. LIU Ning.